|
It was reported the patient was presented to physician in stable condition for elective procedure of primary percutaneous coronary intervention procedure (ppci).The ppci procedure was completed without any complication, the patient was discharged the following day.Next day discharge is normal, as the patient was inpatient prior to the percutaneous coronary intervention (pci).During the procedure, when the dilator was removed from the sheath, prior to placing the impella the physician experienced oozing with the 13cm sheath at the valve.The procedure was delayed for 5 minutes, the issue was resolved by swapping out for another 14f oscor sheath.Minimal blood was lost, no blood product or surgical technique was required to control the oozing.Requesting additional information.
|
|
The following sections were updated in follow-up.A3,b4,g4,g7,h2,h6,h10.The device was used for treatment.Location of device is unknown and the device was not returned for analysis, therefore, the clinical observation could not be confirmed.The investigation will focus on a review of product documentation.The device history record was reviewed to confirm that the device passed all applicable in-process and final inspections per procedure adelante s2s introducer sheath in-process and final inspection, perform pressure and vacuum leak test per procedure,latest revision.This test is performed by qa on 100% of the product.Per ifu.Precuations: when assembling the sheath and dilator, care must be taken to insert the dilator tip straight through the center of the valve membrane in order to prevent inadvertent puncturing of the membrane.Directions for use: slowly retract the guidewire and dilator, leaving the sheath in position.The hemostasis valve will reduce the loss of blood and the inadvertent aspiration of air through the sheath.Introduce the catheter through the hemostasis valve/sheath and advance it into position.Based on the investigation, a capa is not required as findings did not identify a design, labeling or manufacturing non-conformity.In addition, there was no new failure mode identified and the risk remains acceptable.The event will be re-evaluated if additional information becomes available.Oscor will continue to monitor this event type and risk.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report is based upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to the event described in this report.
|